Skip to main content
Premium Trial:

Request an Annual Quote

Helix Closes $200M Series B Financing

NEW YORK (GenomeWeb) – Helix said today that it has closed a $200 million Series B financing round, following an investment from Temasek.

In March, the company had announced its intention to raise $200 million, with initial funding led by DFJ Growth, with participation from Helix's founding investors Illumina, Kleiner Perkins Caufield and Byers, Mayo Clinic, Sutter Hill Ventures, and Warburg Pincus.

Helix plans to use the financing to continue to push the adoption of consumer genomics products, including by expanding its genomics applications. Currently, the firm sells 35 products from 20 partners, which it plans to grow to over 50 products in 2018. This will include health-related products from the Mayo Clinic and PerkinElmer.

"Temasek was the perfect partner for us to continue our growth into the rapidly expanding consumer genomics market both here in the United States and as we look to expand internationally in the coming years," Helix CEO Robin Thurston said in a statement. "This investment further advances our goal to continue to bring accurate health products to the market with partners like Mayo Clinic."

Earlier today, San Carlos, California-based Helix said that it has acquired HumanCode, a Denver, Colorado firm that has developed genetic testing apps for the Helix platform. Helix also said that it will open an office in Denver and will take on the entire HumanCode team.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.